Diindolylmethane in Treating Patients With Nonmetastatic Prostate Cancer That Has Not Responded To Previous Hormone Therapy

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically proven adenocarcinoma of the prostate
• Prostate specific antigen (PSA)-only failure after local therapy (surgery, radiation therapy, brachytherapy, or cryotherapy)
• Rising PSA despite androgen-deprivation therapy with castrate levels of testosterone (\< 50 ng/dL)
• * Two successive rising PSA levels at least 1 week apart
• * PSA ≥ 5 ng/mL
• Patients with a history of combined hormonal therapy must continue luteinizing-hormone releasing-hormone agonist treatment but must demonstrate rising PSA after anti-androgen withdrawal
• No evidence of distant metastasis by bone scan and CT scan
• No known brain metastases requiring active therapy
• PATIENT CHARACTERISTICS:
• ECOG performance status ≤ 3
• Life expectancy ≥ 12 weeks
• Absolute neutrophil count ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• Hemoglobin ≥ 8.0 g/dL
• Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
• SGOT and/or SGPT ≤ 2.5 times ULN AND alkaline phosphatase normal OR alkaline phosphatase ≤ 4 times ULN AND SGOT and/or SGPT normal
• Creatinine clearance ≥ 60 mL/min OR creatinine normal
• Fertile patients must use effective contraception
• None of the following conditions within the past 6 months:
• * Myocardial infarction
• * Severe or unstable angina
• * Symptomatic congestive heart failure
• * Cerebrovascular accident or transient ischemic attack
• * Coronary/peripheral artery bypass grafting
• No other severe acute or chronic medical or psychiatric condition or laboratory abnormality that would preclude study participation
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• At least 28 days since prior radiotherapy
• At least 28 days since prior investigational agents for treatment of prostate cancer
• At least 4 weeks since prior flutamide
• At least 6 weeks since prior bicalutamide
• No other concurrent antineoplastic agents
• No concurrent warfarin-related anticoagulants
• No concurrent proton-pump inhibitor drugs for gastroesophageal reflux disease (e.g., rabeprazole, esomeprazole magnesium, lansoprazole, omeprazole, or pantoprazole sodium)
• No concurrent micronutrient supplements or dietary soy products
• * One daily multivitamin allowed